SLC5A2 and cardiovascular disorder: Accordingly, in patients with type 2 diabetes and established HF with reduced ejection fraction and/or known cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended to reduce risk of worsening HF and cardiovascular death (American Diabetes Association Professional Practice Committee et al., 2022).